Oncology

Non-Small Cell Lung Cancer

Clinical Topic Updates Podcast: Neoadjuvant, Perioperative, and Adjuvant Therapies for Resectable Non–Small Cell Lung Cancer

clinical topic updates by Narjust Florez, MD, FASCO

Overview

Treatment options for resectable non–small cell lung cancer (NSCLC) continue to evolve, with neoadjuvant chemoimmunotherapy, perioperative immunotherapy, and adjuvant targeted therapy creating new opportunities for pathologic response and long-term disease control. Narjust Florez, MD, FASCO, talks about current approaches to treatment selection and sequencing in this NSCLC podcast.

References

Cascone T, Awad MM, Spicer JD, et al; CheckMate 77T Investigators. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024;390(19):1756-1769. doi:10.1056/NEJMoa2311926

Spicer JD, Garassino MC, Wakelee H, et al; KEYNOTE-671 Investigators. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404(10459):1240-1252. doi:10.1016/S0140-6736(24)01756-2

Wu YL, Dziadziuszko R, Ahn JS, et al; ALINA Investigators. Alectinib in resected ALK-positive non–small-cell lung cancer. N Engl J Med. 2024;390(14):1265-1276. doi:10.1056/NEJMoa2310532

Profile

Narjust Florez, MD, FASCO

Associate Medical Director, Cancer Care Access Program
Codirector, Young Lung Cancer Program
Thoracic Medical Oncologist
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, MA